Skip to main content
AAN.com

Abstract

Objective: To explore the association between specific nucleoside reverse transcriptase inhibitors and sensory neuropathies (SNs) and define the modifying roles of hepatitis C (HCV), vitamin B12 deficiency, and impaired glucose tolerance.
Methods: The authors conducted a prospective cohort study of 147 HIV-infected adults at two sites chosen to emphasize demographic differences. Standardized assessments included detailed antiretroviral histories, neurologic examinations, skin biopsies for epidermal nerve quantitation, and quantitative sensory testing.
Results: There were significant differences between subjects at Johns Hopkins University (JHU) and Monash University (MU) in gender, race, HIV transmission route, and HCV seroprevalence. Symptomatic SN was present in 49% at JHU and 55% at MU (χ2 = 4.02, p = 0.134) and was significantly more common in those at least age 40 than younger patients (odds ratio [OR] = 2.87, 95% CI = 1.27, 6.49). After adjusting for site, age, and CD4 cell count, exposure to didanosine (ddI) or stavudine (d4T) was associated with an significantly increased likelihood of symptomatic SN (ddI: OR = 3.21, 95% CI: 1.56, 6.60; d4T: OR = 7.66, 95% CI: 2.89, 20.33). Plasma HIV RNA, lactate, and HCV were not associated with SN. Quantitative vibratory testing identified neuropathy with a positive predictive value of 76% and epidermal nerve fiber densities 59%.
Conclusions: Exposure to stavudine and didanosine was significantly associated with a heightened risk for symptomatic sensory neuropathy. Reduced vibration thresholds and epidermal nerve fiber densities had the highest diagnostic efficiency of the laboratory indicators of neuropathy examined, but were relatively insensitive in isolation.

Get full access to this article

View all available purchase options and get full access to this article.

References

1.
Dubinsky R, Yarchoan R, Dalakas M, Broder S. Reversible axonal neuropathy from the treatment of AIDS and related disorders with 2′,3′-dideoxycytidine (ddC). Muscle Nerve 1989;12:856–860.
2.
Tagliati M, Grinnell J, Godbold J, Simpson DM. Peripheral nerve function in HIV infection. Clinical, electrophysiologic, and laboratory findings. Arch Neurol 1999;56:84–89.
3.
Berger A, Arezzo J, Schaumburg H, et al. 2′,3′-Dideoxycytidine (ddC) toxic neuropathy: a study of 52 patients. Neurology 1993;43:358–362.
4.
Blum A, Dal Pan G, Feinberg J, et al. Low-dose zalcitabine-related toxic neuropathy: frequency, natural history, and risk factors. Neurology 1996;46:999–1003.
5.
Lipkin W, Parry G, Kiprov D, Abrams D. Inflammatory neuropathy in homosexual men with lymphadenopathy. Neurology 1985;35:1479–1483.
6.
Barohn R, Gronseth G, LeForce B, et al. Peripheral nervous system involvement in a large cohort of human immunodeficiency virus–infected individuals. Arch Neurol 1993;50:167–170.
7.
Norton G, Sweeney J, Marriott D, Law M, Brew B. Association between HIV distal symmetric polyneuropathy and Mycobacterium avium complex infection. J Neurol Neurosurg Psychiatry 1997;63:557.
8.
So Y, Holtzman D, Abrams D, Olney R. Peripheral neuropathy associated with acquired immunodeficiency syndrome—prevalence and clinical features from a population-based survey. Arch Neurol 1988;45:945–948.
9.
Cornblath D, McArthur J. Predominantly sensory neuropathy in patients with AIDS and AIDS-related complex. Neurology 1988;38:794–796.
10.
Snider WD, Simpson DM, Nielson S, Gold JW, Metroka CE, Posner JB. Neurological complications of acquired immune deficiency syndrome: analysis of 50 patients. Ann Neurol 1983;14:403–418.
11.
Miller R, Parry G, Pfaeffl W, W L, Lippert R, Kiprov D. The spectrum of peripheral neuropathy associated with ARC and AIDS. Muscle Nerve 1988;11:857–863.
12.
Leger J, Bouche P, Bolgert F, et al. The spectrum of polyneuropathies in patients infected with HIV. J Neurol Neurosurg Psychiatry 1989;52:1369–1374.
13.
Levy R, Bredesen D, Rosenblum M. Neurological manifestations of the acquired immunodeficiency syndrome (AIDS): experience at UCSF and review of the literature. J Neurosurg 1985;62:475–495.
14.
Bacellar H, Munoz A, Miller E, et al. Temporal trends in the incidence of HIV-1-related neurologic diseases: Multicenter AIDS Cohort Study, 1985–1992. Neurology 1994;44:1892–1900.
15.
Childs E, Lyles R, Selnes O, et al. Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Neurology 1999;52:607–613.
16.
Sacktor N, Lyles R, Skolasky R, et al. HIV-associated neurologic disease incidence changes; Multicentre AIDS Cohort Study, 1990–1998. Neurology 2001;56:257–260.
17.
Morgello S, Estanislao L, Simpson D, et al. HIV-associated distal sensory polyneuropathy in the era of highly active antiretroviral therapy. The Manhattan HIV Brain Bank. Arch Neurol 2004;61:546–551.
18.
Watters M, Poff P, Shiramizu B, et al. Symptomatic distal sensory polyneuropathy in HIV after age 50. Neurology 2004;62:1378–1383.
19.
Yarchoan R, Perno C, Thomas R, et al. Phase 1 studies of 2′,3′-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet 1988;1:76–81.
20.
Simpson DM, Tagliati M. Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection. J AIDS 1995;9:153–161.
21.
Browne M, Mayer K, Chafee S, et al. 2′,3′-Didehydro-3′-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial. J Infect Dis 1993;167:21–29.
22.
Skowron G. Biologic effects and safety of stavudine: overview of phase I and II clinical trials. J Infect Dis 1995;171:S113–S117.
23.
Lambert J, Seidlin M, Reichmann R, et al. 2′,3′-Dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial. N Engl J Med 1990;322:1333–1340.
24.
Kieburtz K, Seidlin M, Lambert J, Dolin R, Reichman R, Valentine F. Extended follow-up of peripheral neuropathy in patients with AIDS and AIDS-related complex treated with dideoxyinosine. J AIDS 1992;5:60–64.
25.
Pike I, Nicaise C. The Didanosine Expanded Access Program: safety analysis. CID 1993;16:S63–S68.
26.
Moore RD, Wong W-ME, Keruly JC, McArthur JC. Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea. AIDS 2000;14:273–278.
27.
Lichtenstein K, Armon C, Baron A, et al. Modification of the incidence of drug-associated symmetrical peripheral neuropathy by host and disease factors in the HIV outpatient study cohort. CID 2005;40:148–157.
28.
Simpson D, Evans S, Kitch D, et al. HIV Neuropathy Natural History Cohort Study: clinical and laboratory features, and risk factors for progression: ACTG A5117. Conference on Retroviruses and Opportunistic Infections, 2005, Boston, 2005.
29.
Brew BJ, Tisch S, Law M. Lactate concentrations distinguish between nucleoside neuropathy and HIV neuropathy. AIDS 2003;17:1094–1096. Letter.
30.
Palella F, Delaney K, Moorman A, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853–860.
31.
Tembl J, Ferrer J, Sevilla M, Lago A, Mayordomo F, Vilchez J. Neurologic complications associated with hepatitis C virus infection. Neurology 1999;53:861–864.
32.
Ammendola A, Sampaolo S, Ambrosone L, et al. Peripheral neuropathy in hepatitis-related mixed cryoglobulinemia: electrophysiologic follow-up study. Muscle Nerve 2005;31:382–385.
33.
De Martino L, Sampaolo S, Tucci C, et al. Viral RNA in nerve tissues of patients with hepatitis C infection and peripheral neuropathy. Muscle Nerve 2003;27:102–104.
34.
Lidove O, Cacoub P, Maisonobe T, et al. Hepatitis C virus infection with peripheral neuropathy is not always associated with cryoglobulinaemia. Ann Rheum Dis 2001;60:290–292.
35.
Carr A, Samaras K, Chisholm D, Cooper D. Pathogenesis of HIV-1-protease inhibitor–associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998;351:1881–1883.
36.
Kino T, Chrousos G. AIDS-related insulin resistance and lipodystrophy syndrome. Curr Drug Targets Immune Endocr Metab Disord 2003;3:111–117.
37.
Mehta S, Moore R, Thomas D, Chaisson R, Sulkowski M. The effect of HAART and HCV infection on the development of hyperglycemia among HIV-infected persons. J AIDS 2003;33:577–584.
38.
Jakobsen J, Smith T, Gaub J, Helweg-Larsen S, Trojaborg W. Progressive neurological dysfunction during latent HIV infection. B Med J 1989;299:225–228.
39.
Chavanet P, Giroud M, Lancon J, et al. Altered peripheral nerve conduction in HIV-patients. Cancer Detect Prev 1988;12:249–255.
40.
Chavanet P, Solary E, Giroud M, et al. Infraclinical neuropathies related to immunodeficiency virus infection associated with higher T-helper cell count. J AIDS 1989;2:564–569.
41.
Husstedt IW, Evers S, Reichelt D, et al. Screening for HIV-associated distal-symmetric polyneuropathy in CDC-classification stages 1, 2 and 3. Acta Neurol Scand 2000;101:183–187.
42.
Smith T, Jakobsen J, Gaub J, Helweg-Larsen S, Trojaborg W. Clinical and electrophysiological studies of human immunodeficiency virus–seropositive men without AIDS. Ann Neurol 1988;23:295–297.
43.
Malessa R, Agelink M, Himmelmann M, Kloss T, Mertins L, Brockmeyer N. Nerve conduction changes in asymptomatic HIV-1 seropositive individuals in the absence of other risk factors for neuropathy. Electromyogr Clin Neurophysiol 1996;26:3–8.
44.
Fuller G, Jacobs J, Guiloff R. Subclinical peripheral nerve involvement in AIDS; an electrophysiological and pathological study. J Neurol Neurosurg Psychiatry 1991;54:318–324.
45.
Barohn R, Gronseth G, Amato A, et al. Cerebrospinal fluid and nerve conduction abnormalities in HIV positive individuals. J Neurol Sci 1996;136:81–85.
46.
Bouhassira D, Attal N, Willer J-C, Brasseur L. Painful and painless peripheral sensory neuropathies due to HIV infection: a comparison using quantitative sensory evaluation. Pain 1999;80:265–273.
47.
Huengsberg M, Winer J, Ross J, Shahmanesh M. Thermosensorythreshold: a sensitive test of HIV associated peripheral neuropathy? J Neurovirol 1998;4:433–437.
48.
Herrmann D, McDermott M, Henderson D, et al. Epidermal nerve fiber density. axonal swellings and QST as predictors of HIV distal sensory neuropathy. Muscle Nerve 2004;29:420–427.
49.
Cherry C, McArthur J, Costello K, Woolley I, Mijch A, Wesselingh S. Increasing prevalence of neuropathy in the era of highly active antiretroviral therapy (HAART). Ninth Conference on Retroviruses and Opportunistic Infections, 2002 February 24–28, Seattle, WA, 2002.
50.
McCarthy B, Hsieh S-T, Stocks A, et al. Cutaneous innervation in sensory neuropathies: evaluation by skin biopsy. Neurology 1995;45:1848–1855.
51.
ACTG. AACTG Metabolic Complications Guide. 2000.
52.
Hanley J, McNeil B. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29–36.
53.
Fichtenbaum CJ, Clifford DB, Powderly WG. Risk factors for dideoxynucleoside-induced toxic neuropathy in patients with the human immunodeficiency virus infection. J AIDS 1995;10:169–174.
54.
Keswani S, Hasan D, McArthur JC, Griffin J, Hoke A. An in vitro model of antiretroviral toxic neuropathy in dorsal root ganglion sensory neurons. Ninth Conference on Retroviruses and Opportunistic Infections, 2002 February 24–28, Seattle, WA, 2002.
55.
Valentine F, Seidlin M, Hochester H, Laverty M. Phase I study of 2′,3′-dideowyinosine: experience with 19 patients at New York Medical Center. Rev Infect Dis 1990;12:S534–S539.
56.
Schifitto G, McDermott M, McArthur J, et al. Incidence of and risk factors for HIV-associated distal sensory polyneuropathy. Neurology 2002;58:1764–1768.
57.
Schifitto G, McDermott M, McArthur J, et al. Markers of immune activation and viral load in HIV-associated sensory neuropathy. Neurology 2005;64:842–848.
58.
Dyck P, Dyck P, Larson T, O’Brien P, Velosa J. Patterns of quantitative sensation testing of hypoesthesia and hyperalgesia are predictive of diabetic polyneuropathy: a study of three cohorts. Nerve Growth Factor Study Group. Diabetes Care 2000;23:510–517.
59.
Brown M, Bird S, Watling S, et al. Natural progression of diabetic peripheral neuropathy in the Zenarestat Study population. Diabetes Care 2004;27:1153–1159.
60.
McArthur J, Stocks E, Hauer P, Cornblath D, Griffin J. Epidermal nerve fiber density. Normative reference range and diagnostic efficiency. Arch Neurol 1998;55:1513–1520.
61.
Polydefkis M, Yiannoutsos C, Cohen B, et al. Reduced intraepidermal nerve fiber density in HIV-associated sensory neuropathy. Neurology 2002;58:115–119.
62.
McArthur J, Griffin J. Another tool for the neurologist’s toolbax. Ann Neurol 2005;57:163–167.

Information & Authors

Information

Published In

Neurology®
Volume 66Number 6March 28, 2006
Pages: 867-873
PubMed: 16567704

Publication History

Published online: March 27, 2006
Published in print: March 28, 2006

Permissions

Request permissions for this article.

Authors

Affiliations & Disclosures

C. L. Cherry, MBBS, PhD
From the Johns Hopkins University (R.L.S., J.C., P.H., S.P.R., R.M., K.C., D.T., G.J.E., J.C.M.), Baltimore, MD; and Monash University (C.L.C., S.L.W.), Alfred Hospital, and Burnet Institute (C.L.C., L.L., S.L.W.), Melbourne, Victoria, Australia.
R. L. Skolasky, MA
From the Johns Hopkins University (R.L.S., J.C., P.H., S.P.R., R.M., K.C., D.T., G.J.E., J.C.M.), Baltimore, MD; and Monash University (C.L.C., S.L.W.), Alfred Hospital, and Burnet Institute (C.L.C., L.L., S.L.W.), Melbourne, Victoria, Australia.
L. Lal, BAppSci
From the Johns Hopkins University (R.L.S., J.C., P.H., S.P.R., R.M., K.C., D.T., G.J.E., J.C.M.), Baltimore, MD; and Monash University (C.L.C., S.L.W.), Alfred Hospital, and Burnet Institute (C.L.C., L.L., S.L.W.), Melbourne, Victoria, Australia.
J. Creighton, BA
From the Johns Hopkins University (R.L.S., J.C., P.H., S.P.R., R.M., K.C., D.T., G.J.E., J.C.M.), Baltimore, MD; and Monash University (C.L.C., S.L.W.), Alfred Hospital, and Burnet Institute (C.L.C., L.L., S.L.W.), Melbourne, Victoria, Australia.
P. Hauer, BS
From the Johns Hopkins University (R.L.S., J.C., P.H., S.P.R., R.M., K.C., D.T., G.J.E., J.C.M.), Baltimore, MD; and Monash University (C.L.C., S.L.W.), Alfred Hospital, and Burnet Institute (C.L.C., L.L., S.L.W.), Melbourne, Victoria, Australia.
S. P. Raman, BS
From the Johns Hopkins University (R.L.S., J.C., P.H., S.P.R., R.M., K.C., D.T., G.J.E., J.C.M.), Baltimore, MD; and Monash University (C.L.C., S.L.W.), Alfred Hospital, and Burnet Institute (C.L.C., L.L., S.L.W.), Melbourne, Victoria, Australia.
R. Moore, MD
From the Johns Hopkins University (R.L.S., J.C., P.H., S.P.R., R.M., K.C., D.T., G.J.E., J.C.M.), Baltimore, MD; and Monash University (C.L.C., S.L.W.), Alfred Hospital, and Burnet Institute (C.L.C., L.L., S.L.W.), Melbourne, Victoria, Australia.
K. Carter, BS, PA-C
From the Johns Hopkins University (R.L.S., J.C., P.H., S.P.R., R.M., K.C., D.T., G.J.E., J.C.M.), Baltimore, MD; and Monash University (C.L.C., S.L.W.), Alfred Hospital, and Burnet Institute (C.L.C., L.L., S.L.W.), Melbourne, Victoria, Australia.
D. Thomas, MD
From the Johns Hopkins University (R.L.S., J.C., P.H., S.P.R., R.M., K.C., D.T., G.J.E., J.C.M.), Baltimore, MD; and Monash University (C.L.C., S.L.W.), Alfred Hospital, and Burnet Institute (C.L.C., L.L., S.L.W.), Melbourne, Victoria, Australia.
G. J. Ebenezer, MBBS, MD
From the Johns Hopkins University (R.L.S., J.C., P.H., S.P.R., R.M., K.C., D.T., G.J.E., J.C.M.), Baltimore, MD; and Monash University (C.L.C., S.L.W.), Alfred Hospital, and Burnet Institute (C.L.C., L.L., S.L.W.), Melbourne, Victoria, Australia.
S. L. Wesselingh, BMBS, PhD
From the Johns Hopkins University (R.L.S., J.C., P.H., S.P.R., R.M., K.C., D.T., G.J.E., J.C.M.), Baltimore, MD; and Monash University (C.L.C., S.L.W.), Alfred Hospital, and Burnet Institute (C.L.C., L.L., S.L.W.), Melbourne, Victoria, Australia.
J. C. McArthur, MBBS, MPH
From the Johns Hopkins University (R.L.S., J.C., P.H., S.P.R., R.M., K.C., D.T., G.J.E., J.C.M.), Baltimore, MD; and Monash University (C.L.C., S.L.W.), Alfred Hospital, and Burnet Institute (C.L.C., L.L., S.L.W.), Melbourne, Victoria, Australia.

Notes

Address correspondence and reprint requests to Dr McArthur, Johns Hopkins Hospital, 600 N. Wolfe Street, Meyer 6-109, Baltimore, MD 21287; e-mail: [email protected]

Metrics & Citations

Metrics

Citation information is sourced from Crossref Cited-by service.

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Small-Fiber Neuropathy, Clinical Dermatology Review, 8, 2, (87-94), (2024).https://doi.org/10.4103/cdr.cdr_132_22
    Crossref
  2. Peripheral Neuropathy in Virologically Suppressed People Living with HIV: Evidence from the PIVOT Trial, Viruses, 16, 1, (2), (2023).https://doi.org/10.3390/v16010002
    Crossref
  3. Postural instability in HIV infection: relation to central and peripheral nervous system markers, AIDS, 37, 7, (1085-1096), (2023).https://doi.org/10.1097/QAD.0000000000003531
    Crossref
  4. Epidemiology of HIV-associated peripheral neuropathy in people living with human immunodeficiency virus infection in Greece, International Journal of STD & AIDS, 33, 11, (978-986), (2022).https://doi.org/10.1177/09564624221119305
    Crossref
  5. Treatment and Management of Infectious, Granulomatous, and Toxic Neuromuscular Disorders, Neuromuscular Disorders, (345-379), (2022).https://doi.org/10.1016/B978-0-323-71317-7.00016-0
    Crossref
  6. Clinical Characteristics of Peripheral Neuropathy in Kenyan Patients with HIV Infection Compared with Patients with Concurrent HIV Infection and Diabetes Mellitus, Diabetes Therapy, 13, 3, (441-451), (2022).https://doi.org/10.1007/s13300-022-01205-3
    Crossref
  7. Higher iron stores and the HFE 187C>G variant delay onset of peripheral neuropathy during combination antiretroviral therapy, PLOS ONE, 15, 10, (e0239758), (2020).https://doi.org/10.1371/journal.pone.0239758
    Crossref
  8. Human immunodeficiency virus–related peripheral neuropathy: A systematic review and meta‐analysis, European Journal of Neurology, 28, 4, (1420-1431), (2020).https://doi.org/10.1111/ene.14656
    Crossref
  9. Disease-modifying therapy for HIV-related distal symmetrical polyneuropathy (including antiretroviral toxic neuropathy), Cochrane Database of Systematic Reviews, (2020).https://doi.org/10.1002/14651858.CD013716
    Crossref
  10. Chronic diabetic peripheral neuropathic pain: psychometric properties of pain and physical function outcome measures, Physical Therapy Reviews, 23, 6, (317-329), (2018).https://doi.org/10.1080/10833196.2018.1517072
    Crossref
  11. See more
Loading...

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share